Noah R Gubner1, Joseph Guydish2, Gary L Humfleet3, Neal L Benowitz4, Sharon M Hall3. 1. Department of Psychiatry, University of California, San Francisco, CA, USA; Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, CA, USA. Electronic address: noah.gubner@ucsf.edu. 2. Department of Psychiatry, University of California, San Francisco, CA, USA; Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, CA, USA. 3. Department of Psychiatry, University of California, San Francisco, CA, USA. 4. Departments of Medicine and Bioengineering and Therapeutic Sciences, University of California San Francisco, CA, USA.
Abstract
BACKGROUND: Individual differences in the rate of nicotine metabolism contribute to differences in tobacco use, dependence, and efficacy of smoking cessation treatments and can be assessed using the nicotine metabolite ratio (NMR), a validated biomarker for CYP2A6 activity. Despite the high cigarette smoking rates observed in opioid users, no data have been reported on NMR among this population as they has been largely excluded from previous studies that have examined the relationship between tobacco use characteristics and rate of nicotine metabolism. METHODS: A linear regression model was used to examine the relationship between tobacco use characteristics and NMR among smokers taking buprenorphine for opioid dependency (N=141). The relationship between buprenorphine dose and NMR was also examined. All participants were enrolled in an intervention designed to promote cigarette-smoking cessation, though participants did not need to stop smoking to enroll. RESULTS AND CONCLUSIONS: Rate of nicotine metabolism assessed using the NMR was positively associated with cigarettes smoked in the past 24h, but was not related to time to first cigarette or past year quit attempts. Dose of buprenorphine was not associated with NMR, suggesting no association with rate of nicotine metabolism. Our results suggest that NMR is related to tobacco use among persons enrolled in opioid treatment, as reported in general population smokers and may be a useful biomarker to include in future research assessing efficacy of tobacco cessation interventions in this population.
BACKGROUND: Individual differences in the rate of nicotine metabolism contribute to differences in tobacco use, dependence, and efficacy of smoking cessation treatments and can be assessed using the nicotine metabolite ratio (NMR), a validated biomarker for CYP2A6 activity. Despite the high cigarette smoking rates observed in opioid users, no data have been reported on NMR among this population as they has been largely excluded from previous studies that have examined the relationship between tobacco use characteristics and rate of nicotine metabolism. METHODS: A linear regression model was used to examine the relationship between tobacco use characteristics and NMR among smokers taking buprenorphine for opioid dependency (N=141). The relationship between buprenorphine dose and NMR was also examined. All participants were enrolled in an intervention designed to promote cigarette-smoking cessation, though participants did not need to stop smoking to enroll. RESULTS AND CONCLUSIONS: Rate of nicotine metabolism assessed using the NMR was positively associated with cigarettes smoked in the past 24h, but was not related to time to first cigarette or past year quit attempts. Dose of buprenorphine was not associated with NMR, suggesting no association with rate of nicotine metabolism. Our results suggest that NMR is related to tobacco use among persons enrolled in opioid treatment, as reported in general population smokers and may be a useful biomarker to include in future research assessing efficacy of tobacco cessation interventions in this population.
Authors: Caryn Lerman; Robert A Schnoll; Larry W Hawk; Paul Cinciripini; Tony P George; E Paul Wileyto; Gary E Swan; Neal L Benowitz; Daniel F Heitjan; Rachel F Tyndale Journal: Lancet Respir Med Date: 2015-01-12 Impact factor: 30.700
Authors: Timothy B Baker; Megan E Piper; Danielle E McCarthy; Daniel M Bolt; Stevens S Smith; Su-Young Kim; Suzanne Colby; David Conti; Gary A Giovino; Dorothy Hatsukami; Andrew Hyland; Suchitra Krishnan-Sarin; Raymond Niaura; Kenneth A Perkins; Benjamin A Toll Journal: Nicotine Tob Res Date: 2007-11 Impact factor: 4.244
Authors: Sharon M Hall; Gary L Humfleet; James J Gasper; Kevin L Delucchi; David F Hersh; Joseph R Guydish Journal: Nicotine Tob Res Date: 2018-04-02 Impact factor: 4.244
Authors: Robert A Schnoll; Morgan Thompson; Katrina Serrano; Frank Leone; David Metzger; Ian Frank; Robert Gross; Karam Mounzer; Rachel F Tyndale; Jessica Weisbrot; Miles Meline; Ronald G Collman; Rebecca L Ashare Journal: J Acquir Immune Defic Syndr Date: 2019-02-01 Impact factor: 3.731
Authors: Arash Etemadi; Hossein Poustchi; Antonia M Calafat; Benjamin C Blount; Victor R De Jesús; Lanqing Wang; Akram Pourshams; Ramin Shakeri; Maki Inoue-Choi; Meredith S Shiels; Gholamreza Roshandel; Gwen Murphy; Connie S Sosnoff; Deepak Bhandari; Jun Feng; Baoyun Xia; Yuesong Wang; Lei Meng; Farin Kamangar; Paul Brennan; Paolo Boffetta; Sanford M Dawsey; Christian C Abnet; Reza Malekzadeh; Neal D Freedman Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-01-08 Impact factor: 4.254
Authors: Cheryl Oncken; Erin L Mead; Ellen A Dornelas; Chia-Ling Kuo; Heather Z Sankey; Henry R Kranzler; Sheila Thurlow Journal: Nicotine Tob Res Date: 2020-05-26 Impact factor: 4.244
Authors: Henry R Kranzler; Yukiko Washio; Leah R Zindel; Kevin G Lynch; Dennis Hand; Rachel F Tyndale; Cheryl Oncken; Robert Schnoll Journal: Nicotine Tob Res Date: 2020-10-08 Impact factor: 4.244